Pharmacoeconomics

Efavirenz-Based Therapy More Cost-Effective Than Indinavir Regimens

Published in AIDS Weekly, April 9th, 2001

by Michael Greer, staff medical writer - Antiretroviral treatment regimens containing efavirenz are markedly more cost-effective than similar therapies based on indinavir, according to researchers in Massachusetts.

Writing in the journal Pharmacoeconomics, J.J. Caro and colleagues described the results of their study comparing triple therapies with either efavirenz or indinavir combined with zidovudine and lamivudine.

They found that efavirenz-based regimens not only were significantly to produce positive results, but also to save substantial amounts of money as well.

Efavirenz-based triple therapy produced five-year...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2001-04-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry